

IVTIP Spring Meeting 2010 Integrated *In Vitro* Testing Strategies

May 18, 2010

Hotel Ramada Encore, CH-1227 Carouge-Geneva, Switzerland

The *In Vitro Testing Industrial Platform* (IVTIP) has the pleasure to invite you to the Spring Meeting on the 18th May 2010, hosted by the IVTIP member company **Epithelix** (<http://www.epithelix.com>).

Inspired by the latest US *Environmental Protection Agency* (EPA) strategic plan for evaluating the toxicity of chemicals 'Toxicity Testing in the 21st Century: A vision and a strategy', IVTIP organized a meeting (November 26th 2009, Edegem, Belgium) to discuss among scientists, key opinion leaders, developers and users of 3Rs-related tests and strategies how this vision could be transformed into a visionary reality.

One of the emerging concepts focused on integrating a defined number of tests modeling *in vivo*-relevant and well-characterized toxicity pathways representing mechanistic endpoints.

Realizing that integrated *in vitro* testing strategies (ITS) currently are used in several sectors for early decision-making during product discovery and development, IVTIP have organized a meeting with the theme:

Integrated *In Vitro* Testing Strategies - Implementation challenges -

During this meeting IVTIP wants to give people within the field an opportunity to share their experiences related to the organization and implementation of ITS with:

- (i) scientists and toxicologists from industry who are working with ITS on a daily basis or who are to embark on developing such strategies,
- (ii) representatives of Framework Program supported projects aimed at developing tests and testing strategies for regulatory purposes,
- (iii) young scientists and students with an ambition to engage in 3Rs research.

The overall objective of the meeting is to establish a platform of best practice, and to highlight the importance of the applicability of the individual tests as well as the testing strategy itself.

The format of the meeting will be primarily a discussion forum fed with views and opinions brought forward by a number of distinguished speakers. The outcome will be a white paper on best practice and criteria for assuring applicability.

The meeting program will be posted on our website (www.ivtip.org) and distributed by mid April. In the mean time keep this date free and please join us on the 18th May 2010 in Geneva. The registration fee will be €100 for industry, €70 for academia, and €25 for students.

We are looking forward to meeting you there.

Erwin L Roggen, President

ivtip@planet.nl - elro@novozymes.com - bart@deweverconsulting.be - www.ivtip.org